Cantor Fitzgerald’s Astria Therapeutics ATXS Stock Holding History

Cantor Fitzgerald’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-224,077	Closed	-$2.93M	–	262
2025 Q4	$2.93M	Buy	+224,077	New	+$2.68M	0.04%	130
2025 Q3	–	Sell	-54,635	Closed	-$293K	–	384
2025 Q2	$293K	Buy	+54,635	New	+$265K	0.01%	269

Cantor Fitzgerald's ATXS Position: Q1 2026 in Review

Cantor Fitzgerald sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 224,077 shares — an estimated $2.93M sold.

Cantor Fitzgerald first reported a position in ATXS in Q2 2025 and held it in 2 quarters. The position peaked at $2.93M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Cantor Fitzgerald reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Cantor Fitzgerald sold 224,077 Astria Therapeutics shares in Q1 2026, an estimated $2.93M.
Cantor Fitzgerald first reported a position in Astria Therapeutics in Q2 2025 and held it in 2 quarters.
Cantor Fitzgerald's Astria Therapeutics position peaked at $2.93M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.